Fracture Risk Stratification: Translating Science to Clinical Practice

Christopher Shuhart, MD, MHA, CCD

Saturday, April 11, 2026, 10:00am to 10:30am Eastern Time (NY/USA)

Description

Estimating fracture risk should be an integral part of bone health assessment. Multiple tools and strategies are available - some well validated, others more controversial but nonetheless potentially useful. We'll try to explore as many avenues as possible to get the fullest understanding of fracture risk for treatment recommendation.

Summary of How to use TBS in Clinical Practice

John Schousboe, MD, PhD, CCD

Saturday, April 11, 2026, 10:30am to 11:00am EDT

Description

This presentation will first review the principle behind TBS, and why it correlates with other measures of trabecular bone microarchitecture and bone strength. We will review the effects of degenerative changes, fracture and other artifacts on TBS values. We will then review how the addition of TBS can alter fracture risk assessment and highlight clinical scenarios where the addition of TBS may alter fracture risk management decisions.

How to diagnose and manage the spectrum of CKD-MBD

Thomas L. Nickolas, MD, MS, FASN, FASBMR

Saturday, April 11, 2026, 11:00am to 11:45am Eastern Time (NY/USA)

Description

Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD) is a complex disorder of bone and mineral metabolism that affects all patients with CKD, in particular as kidney dysfunction worsens. CKD-MBD is associated with abnormalities in the Vitamin D-Parathyroid axis and Osteoporosis. This session will review the epidemiology of CKD-MBD and its complications and strategies to diagnose and manage the disorder, with a focus on patient-centered outcomes.

Imaging Evaluation of Suspected Fractures and Osseous Stress Injury

Erwin E. Xia, MD, CCD

Saturday, April 11, 2026, 12:00 pm to 12:30 pm Eastern Time (NY/USA)

Description

This session will provide an overview of fractures from a radiology perspective. Real life cases will be shown. The imaging modalities covered include radiographs, MRI, and CT.

Orthopaedic Fracture Management in Metabolic Bone Disease

Kathryn Barth, MD

Saturday, April 11, 2026, 12:30 pm to 1:00 pm EDT

Product Theater by Radius Health - Bone Matters: Understanding Fracture Risk

Kristi Tough DeSapri, MD, MSCP, CCD    Founding Physician; Bone and Body Women’s Health, pLLC

Moderator: Laurie Neroni

Saturday, April 11, 2026, 1:00pm to 2:00pm Eastern Time (NY/USA)

Please join us for an informative session led by Dr. Kristi Tough DeSapri, MD, MSCP, CCD, an expert in osteoporosis management and founder of Bone and Body Women’s Health in Winnetka, IL. Dr. DeSapri will provide valuable insights into an approved treatment for men and postmenopausal women at high risk for fractures. The presentation will cover essential topics such as the significance of bone building, mechanism of action, and key outcomes from clinical trials in both men and postmenopausal women.

Product Theaters are sponsored presentations and there is no credit available.

Atypical Femur Fracture: Identification and Management

E. Michael Lewiecki, MD, FACP, FACE, CCD

Saturday, April 11, 2026, 2:00pm to 2:30 pm Eastern Time (NY/USA)

Description

AFFs are associated with some osteoporosis treatments and may occur without any treatment. The risk of AFF for most patients is very low and can be minimized with appropriate care. This presentation will address strategies for early recognition AFF, treatment of incomplete and complete AFF, and management of osteoporosis after AFF.

Atypical Femoral Fracture: An Update

WuQiang Fan, MD, PhD

Saturday, April 11, 2026, 2:30pm to 3:00 pm Eastern Time (NY/USA)

Objectives

In this session, we will:

1. Review the risks, epidemiological patterns, and clinical features of atypical femoral fractures (AFFs).
2. Discuss differential management of AFF linked to bisphosphonate or denosumab therapy, including areas of uncertainty.
3. Evaluate the clinical implications of current AFF knowledge in the context of anti-osteoporosis pharmacotherapy.

Pediatric Metabolic Bone Disease

Diego Jaramillo, MD, MPH, FACR

Saturday, April 11, 2026, 3:00pm to 3:45pm Eastern Time (NY/USA)

Description

The session will focus on imaging findings of metabolic and genetic disorders of childhood that affect bone mineral density. The session will review the impact of growth on the manifestation of metabolic disorders, and how these disorders affect bone formation. The session will also discuss the diagnosis by imaging of complications that can arise from abnormal bone metabolism in children.

Hormone Replacement Therapy: Updates and Fracture Data

Sherri-Ann Burnett-Bowie, MD, MPH

Saturday, April 11, 2026, 4:00pm to 4:30pm Eastern Time (NY/USA)

Bone Biopsy: Clinical Indications, Limitations

Charles Ginsberg, MD, MAS

Saturday, April 11, 2026, 4:30pm to 5:00pm Eastern Time (NY/USA)

Description

This session will evaluate the role of bone biopsy in the management of metabolic bone disease. It will focus on how biopsy is done, what information it provides, and how it can be implemented in the management of bone disease. The talk will explore important areas of bone management like management in patients with kidney disease, abnormalities of bone turnover and patients who have failed therapies.

Racial/Ethnic Differences in BMD and Fracture Rate: Dispelling Myths

Angela M. Cheung, MD, PhD, FRCPC

Description & Objectives

In this session, I will be examining differences in bone mineral density (BMD) and fracture risks in different racial and ethnic populations. BMD is determined by a complex interplay of genetic factors, lifestyle, hormonal levels, and physical characteristics, with approximately 60% to 80% of peak bone mass variance attributed to genetics. Race and ethnicity are significant independent determinants of BMD, influencing peak bone mass, rate of bone loss, and overall fracture risk. I will also be discussing how this information can be used to translate to better patient care.

After this session, the participant will be able to:

• Understand that race and ethnicity are significant determinants of BMD and fracture risks
• Explain why these differences may create myths and affect care
• Individualize osteoporosis treatments based on race and ethnicity

Kyphoplasty/vertebroplasty: Indications and Outcomes

Daniel Holzwanger, MD

Sunday, April 12, 2026, 10:00am to 10:30am Eastern Time (NY/USA)

How do GLP1s Affect Sarcopenia and MBD/OP

Shirine E. Usmani, MD, PhD, FRCPC

Sunday, April 12, 2026, 10:30am to 11:00am Eastern Time (NY/USA)

Description

GLP-1 receptor agonists are now widely used for the management of diabetes and overweight/obesity.  Concerns have been raised about their potential impact on skeletal muscle and bone density. This talk will look at the evidence to date regarding how this class of medication impacts bone and muscle health and will highlight future areas of investigation.

How to Sequence Anabolics/Antiresorptives

Sabashini Ramchand, MBBS

Sunday, April 12, 2026, 11:00am to 11:45am Eastern Time (NY/USA)

Description and Objectives

Interactive session on the topic of optimizing the sequence of osteoporosis therapies for maximum benefit.

After this session, participants should be able to:

1. Evaluate the clinical evidence supporting the initiation of treatment with osteo-anabolic drugs rather than anti-resorptive drugs for patients at very high or imminent risk of fracture.
2. Identify the pharmacological "off-sets" of different osteoporosis therapies.
3. Implement effective transition protocols when moving from one therapy class to another, with a specific focus on the mandatory follow-up for denosumab and anabolic therapies.

Diagnosing Sarcopenia with DXA: Clinical Usefulness and Limitations

Gustavo Duque, MD, PhD, FRACP, FGSA

Sunday, April 12, 2026, 12:00pm to 12:30pm Eastern Time (NY/USA)

Description

This talk will examine the role of DXA in diagnosing sarcopenia, highlighting its accessibility and value for estimating lean mass in clinical and research settings. It will critically discuss key limitations, including variability across devices, cut-off definitions, and the inability of DXA to capture muscle mass, quality and function. Practical implications for clinicians will be addressed, with guidance on how to interpret DXA findings within a comprehensive sarcopenia assessment.
  

Clinical Application of BTM: What does the data say and how do we apply?

Richard Eastell, MD

Sunday, April 12, 2026, 12:30 pm to 1:00pm Eastern Time (NY/USA)

Advancing Osteoporosis Management: Treatment Monitoring and Opportunistic Case-Finding with Trabecular Bone Score

Sunday, April 12, 2026, 1:00pm to 2:00pm Eastern Time (NY/USA)

Part 1: Trabecular Bone Score v4 and Treatment Responsiveness: Evidence from a Systematic Review and Meta-analysis
Summary:
This session will be presented by Dr Enisa Shevroja, MD, PhD, bone specialist and clinical researcher at the Bone Diseases Unit, CHUV Lausanne (Centre Hospitalier Universitaire Vaudois), Switzerland.
The presentation synthesizes evidence from randomized and prospective treatment studies to evaluate the responsiveness of TBS to osteoporosis therapies. The meta-analysis demonstrates consistent, treatment-specific changes in TBS that are biologically coherent with known effects on trabecular microarchitecture. These findings are examined in the context of methodological refinements introduced in TBS v4, including direct tissue thickness correction aimed at improving longitudinal precision.
Collectively, the accumulating clinical evidence supports a broader understanding of TBS within therapeutic assessment and suggests that combining TBS with BMD in longitudinal monitoring may enable a more tailored and biologically informed approach to osteoporosis management.
TBS, derived from the same DXA scan as BMD, has been reimbursed in the United States since 2022.

Part 2:  TBS Reveal: AI-enabled Bone Fragility Assessment from Routine X-rays
Summary:
This session will be presented by Prof Karen Hind, Honorary Professor at Lancaster Medical School, UK, and Vice President of Clinical Affairs, Research and Innovation at Medimaps Group.
Despite established diagnostic tools, it is estimated that up to 70% of individuals at risk of fracture remain unidentified or untreated for osteoporosis. TBS Reveal* has been developed to help close this gap by supporting opportunistic case-finding within everyday clinical practice.
The software enables physicians to assess bone fragility from X-rays that are already being performed for other clinical indications. No additional scans, radiation exposure, or disruption to workflow are required. By analysing the existing image, TBS Reveal provides a clear bone fragility category to support timely follow-up.
In this session, real-world performance data will be presented alongside examples of how this approach can fit naturally into routine radiology and orthopedic pathways. The discussion will focus on practical clinical value - identifying patients who might otherwise be missed, informing conversations about bone health, and supporting earlier, more proactive management before a fracture occurs.
*TBS Reveal is currently available as an RPO, and is pending FDA approval (SaMD).

Product Theaters are sponsored presentations and there is no credit available.

Beyond Osteoporosis: Imaging Spectrum of Metabolic Bone Disease and Diagnoses You Don’t Want to Miss

Kevin R. Math, MD

Sunday, April 12, 2026, 2:00pm to 2:45pm Eastern Time (NY/USA)

Description

While much of our clinical focus is the diagnosis and management of osteoporosis, it is important to recognize the characteristic imaging features of other causes of decreased or increased bone mineral density, pathologic fracture, and other disorders that may mimic osteoporosis. This talk reviews the spectrum of imaging findings of common (and some uncommon) metabolic bone diseases, differential diagnosis, and pearls and pitfalls for accurate diagnosis. Examples of delayed or missed diagnosis will be highlighted.

Opportunistic Imaging: Using AI to Detect OP on Routine Images

Miriam A. Bredella, MD, MBA

Sunday, April 12, 2026, 3:00pm to 3:45pm Eastern Time (NY/USA)

Description

This talk explores how AI can transform opportunistic imaging, mining routinely acquired imaging studies, to detect low bone density and identify patients at risk for osteoporosis without additional costs or radiation. The end-to-end pipeline from algorithm development and external validation to workflow integration and reporting, highlighting performance, calibration, and generalizability across sites and scanners will be discussed. Real-world case studies will illustrate clinical impact on fracture risk stratification and care pathways and implementation logistics.